Exploiting the uniqueness of the soloMERTM technology for the development of next-generation super-potent drug modalities for chronic autoimmune inflammation diseases and beyond - April 2022.
Disegni ruby arcobaleno da colorare. Research in the IDM is led by over 34 independent principal investigators in the basic clinical and public health sciences and has a strong translational focus. Grant and contract funding is sourced from the US National Institutes of Health the Bill Melinda Gates Foundation The Wellcome Trust EDCTP the South African Medical Research Council the National Research.